# A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer

> **NCT06608537** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 52 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** neoadjuvant SCRT followed by Sintilimab plus CAPOX

## Key facts

- **NCT ID:** NCT06608537
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-01
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06608537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06608537, "A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06608537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*